LONDON (Reuters) -Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes and obesity medicines Ozempic, Wegovy and Rybelsus, which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback